Your browser is no longer supported. Please, upgrade your browser.
Settings
JAGX [NASD]
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own0.70% Shs Outstand44.81M Perf Week-7.31%
Market Cap115.03M Forward P/E- EPS next Y-0.63 Insider Trans-0.13% Shs Float40.90M Perf Month-28.91%
Income-45.70M PEG- EPS next Q-0.18 Inst Own19.70% Short Float3.61% Perf Quarter-50.41%
Sales7.00M P/S16.43 EPS this Y88.90% Inst Trans79.79% Short Ratio0.92 Perf Half Y-62.46%
Book/sh0.71 P/B3.39 EPS next Y19.20% ROA-84.20% Target Price4.50 Perf Year116.36%
Cash/sh0.46 P/C5.23 EPS next 5Y40.00% ROE-220.40% 52W Range0.56 - 13.41 Perf YTD-1.43%
Dividend- P/FCF- EPS past 5Y- ROI-85.40% 52W High-82.03% Beta1.55
Dividend %- Quick Ratio3.20 Sales past 5Y105.10% Gross Margin59.60% 52W Low334.23% ATR0.23
Employees34 Current Ratio3.50 Sales Q/Q-87.50% Oper. Margin- RSI (14)21.60 Volatility7.23% 7.10%
OptionableYes Debt/Eq0.80 EPS Q/Q76.40% Profit Margin- Rel Volume0.63 Prev Close2.37
ShortableYes LT Debt/Eq0.76 EarningsAug 13 BMO Payout- Avg Volume1.61M Price2.41
Recom1.50 SMA20-23.56% SMA50-36.48% SMA200-52.10% Volume1,018,202 Change1.69%
Jul-07-21Initiated Cantor Fitzgerald Overweight $5
Jul-11-17Initiated Rodman & Renshaw Buy $2
Sep-16-21 08:30AM  
Sep-15-21 08:30AM  
Sep-14-21 08:30AM  
Sep-09-21 08:30AM  
Sep-07-21 02:32PM  
12:12PM  
Sep-03-21 04:15PM  
12:00PM  
Aug-23-21 08:30AM  
Aug-19-21 08:30AM  
Aug-17-21 08:30AM  
Aug-13-21 09:00PM  
07:30AM  
Aug-10-21 04:30PM  
08:30AM  
Aug-06-21 04:15PM  
Jul-28-21 08:30AM  
Jul-26-21 08:30AM  
Jul-23-21 04:15PM  
Jul-19-21 08:30AM  
Jul-14-21 08:30AM  
Jul-09-21 04:15PM  
Jun-23-21 08:30AM  
Jun-22-21 07:17PM  
Jun-11-21 04:15PM  
Jun-04-21 04:15PM  
Jun-02-21 08:30AM  
Jun-01-21 08:30AM  
08:30AM  
May-26-21 08:30AM  
May-20-21 08:30AM  
May-19-21 11:00AM  
08:30AM  
May-18-21 08:30AM  
May-17-21 08:00AM  
May-14-21 04:30PM  
08:30AM  
May-11-21 08:30AM  
Apr-29-21 09:29AM  
08:00AM  
Apr-21-21 08:30AM  
Apr-19-21 08:30AM  
Apr-16-21 01:52PM  
Apr-15-21 08:30AM  
Apr-14-21 08:30AM  
Apr-08-21 08:30AM  
Apr-06-21 08:30AM  
Apr-02-21 04:15PM  
Mar-31-21 04:15PM  
Mar-30-21 08:30AM  
Mar-22-21 10:10AM  
Mar-15-21 08:30AM  
Mar-09-21 07:30AM  
Mar-05-21 12:26PM  
08:30AM  
Feb-25-21 10:24PM  
Feb-23-21 08:30AM  
Feb-19-21 04:40PM  
Feb-18-21 01:11PM  
08:30AM  
Feb-15-21 10:44AM  
Feb-12-21 01:54PM  
11:57AM  
Feb-09-21 08:30AM  
Feb-08-21 09:51AM  
Feb-04-21 08:42AM  
Feb-03-21 08:30AM  
Jan-26-21 08:45AM  
Jan-22-21 04:15PM  
02:26PM  
08:30AM  
Jan-21-21 08:30AM  
Jan-20-21 08:30AM  
Jan-15-21 08:30AM  
Jan-13-21 08:00AM  
08:00AM  
Jan-12-21 08:30AM  
Jan-11-21 08:30AM  
Jan-08-21 07:44PM  
Jan-06-21 08:30AM  
Jan-05-21 12:54PM  
09:55AM  
Dec-28-20 10:16AM  
Dec-24-20 10:02AM  
Dec-23-20 01:08PM  
08:30AM  
Dec-22-20 12:00PM  
Dec-15-20 08:30AM  
Dec-10-20 08:30AM  
Dec-07-20 08:30AM  
Dec-04-20 08:30AM  
Dec-01-20 10:26AM  
Nov-30-20 10:20AM  
08:30AM  
Nov-24-20 09:00AM  
Nov-16-20 08:00AM  
Nov-10-20 04:15PM  
Oct-29-20 08:30AM  
Oct-21-20 07:45AM  
Oct-20-20 08:30AM  
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOCHNOWSKI JAMES JDirectorJun 04Sale1.74152264954,390Jun 07 04:38 PM
BOCHNOWSKI JAMES JDirectorJun 03Sale1.75292511954,542Jun 07 04:38 PM